Amgen Inc. (NASDAQ:AMGN) is favored by Jim Cramer for its cholesterol and weight loss treatments, with a solid yield of over 2.7%. The company develops therapeutics for various diseases like cancer and autoimmune conditions, making it a strong investment choice.

Cramer highlighted Amgen’s success in the healthcare sector, with a 20% increase in stock value since late September. The company reported impressive quarterly results and promising heart attack prevention trial data for its cholesterol drug Repatha, showing potential for further growth.

While AMGN is a promising investment, some AI stocks may offer better returns. Investors seeking undervalued AI stocks can explore opportunities in companies benefiting from Trump-era tariffs and onshoring trends for potentially higher gains.

For more stock recommendations and investment opportunities, check out Insider Monkey’s articles on stocks with potential for significant growth.

Read more at Yahoo Finance: Jim Cramer Shows Confidence in Amgen